Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0815 • ACR Convergence 2025
Neuropathic-like Pain Characteristics Predict Worse Pain Outcomes in Early Rheumatoid Arthritis: a Prospective Cohort Study with Embedded Neuroimaging Evaluation
Eoin Kelleher¹, Amanda Wall¹, Isabelle Brennan², Robert Murphy¹, Antonella Delmis¹, John Davis³, Vishvarani Wanigasekera⁴, Irene Tracey¹ and Anushka Irani⁵, ¹University of Oxford, Oxford, United Kingdom, ²University of Cambridge, Cambridge, United Kingdom, ³Mayo Clinic, Rochester, MN, ⁴University of Oxford, Oxford, ⁵Mayo Clinic, Jacksonville, FL
Background/Purpose: Despite effective control of inflammation in rheumatoid arthritis (RA), persistent and severe pain remains a clinical challenge. Dysregulated pain processing in the central nervous…
Abstract Number: 0501 • ACR Convergence 2025
Phase 1b Study of SBT777101, an Engineered CAR-T-Regulatory Cell Product, in Patients With Rheumatoid Arthritis: Interim Demographics and Safety
Sarah Baxter¹, Ari Bitton², Victor Yuan², Fawad Aslam³, Gregory Challener⁴, Jonathan Graf⁵, Melissa Griffith⁶, Tamiko Katsumoto⁷, Minna Kohler⁸, Elena Massarotti⁹, Larry Moreland¹⁰, Allison Rosenthal¹¹, Jeffrey Sparks⁹, Steven Vlad¹², Janeth Yinh¹³, Andrew Clauw¹⁴, Sally Arai¹⁵, Alexander Carvidi⁵, Angela Chavez¹⁶, Olivia Gabriel¹⁷, Rita Gyurko¹⁷, Megan Hall¹⁸, Jennifer Seifert¹⁹, Emma Stainton¹⁵, Michelle Blake¹, Sabrina Fox-Bosetti², Mark Fromhold¹, Mindy Jensen²⁰, Herve Lebrec², Sean O'Bryan², Amanda Pace²¹, Mei-Lun Wang², Yuanyuan Xiao², Joseph Arron² and Jeffrey Bluestone²², ¹Sonoma Biotherapeutics, Seattle, WA, ²Sonoma Biotherapeutics, San Francisco, CA, ³Mayo Clinic, Arizona, Scottsdale, AZ, ⁴MGH, Boston, MA, ⁵UCSF, San Francisco, CA, ⁶University of Colorado, Aurora, CO, ⁷Division of Immunology and Rheumatology, Stanford University, Millbrae, CA, ⁸Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁹Brigham and Women's Hospital, Boston, MA, ¹⁰University of Colorado, Denver, CO, ¹¹Mayo Clinic, Phoenix, ¹²Tufts Medicine, Boston, MA, ¹³Massachusetts General Hospital, Boston, MA, ¹⁴Univ of Colorado, Aurora, CO, ¹⁵Stanford, Palo Alto, CA, ¹⁶Tufts, Boston, MA, ¹⁷BWH, Boston, MA, ¹⁸Mayo, Scottsdale, AZ, ¹⁹University of Colorado and Oklahoma Medical Research Foundation, Aurora, CO, ²⁰Sonoma Bio, Seattle, ²¹Sonoma Bio, Seattle, WA, ²²Sonoma Biotherapeutics, South San Francisco, CA
Background/Purpose: Regulatory T cells (Tregs) modulate inflammation, maintain self-tolerance, and promote tissue repair, and thus hold promise as a versatile therapeutic tool. Autologous polyclonal Tregs…
Abstract Number: 0483 • ACR Convergence 2025
Safety of JAK inhibitors (JAKi) in chronic inflammatory arthritis (CIA): an observational study
Clara De Miguel¹, Héctor Vega², Marta Sánchez², Esther Toledano³, Pedro Pablo Bermejo⁴, Leonor Laredo⁵, José Alberto Peña⁶, María Teresa Benítez⁷, DALIFER FREITES⁸, LETICIA LEON⁹ and lydia Abasolo Alcazar¹⁰, ¹Rheumatology Service, San Carlos Clinical Hospital, Madrid, Spain, ²Complutense University of Madrid, Madrid, Spain, ³Rheumatology Service, San Carlos Clinical Hospital, Madrid, Spain, ⁴Clinical Pharmacology Service, San Carlos Clinical Hospital, MADRID, Madrid, Spain, ⁵Hospital Clinico San Carlos, MADRID, Madrid, Spain, ⁶Pharmacy Service San Carlos Clinical Hospital, MADRID, Madrid, Spain, ⁷San Carlos Clinical Hospital, MADRID, Madrid, Spain, ⁸Rheumatology Service, San Carlos Clinical Hospital, Madrid, Madrid, Spain, ⁹Fundación Investigación Biomédica Hospital Clínico San Carlos, IdISSC; Universidad Camilo Jose Cela, MADRID, Madrid, Spain, ¹⁰IdISSC. HCSC, Madrid, Madrid, Spain
Background/Purpose: Rheumatoid arthritis (RA), psoriatic arthritis (PsA), and spondyloarthritis (SpA) are chronic inflammatory arthritis (CIAs). Janus kinase inhibitors (JAKis) have emerged as a promising therapeutic…
Abstract Number: 0466 • ACR Convergence 2025
Pilot Study Demonstrates Altered Intestinal Mucosal Microbiome in Patients with Rheumatoid Arthritis versus Control Subjects
Tulsi Joishy¹, Anastasiia Phothisane², Phicharmon Kulapatana² and Michelle Ormseth¹, ¹Vanderbilt University Medical Center, Nashville, ²Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease that is thought to originate at the mucosa. Despite the mucosa’s importance, few studies have examined…
Abstract Number: 0449 • ACR Convergence 2025
Consistency of CDAI Low-Disease Activity (LDA) Outcomes with Time in a Large US Registry: Association With Patient-Reported Clinical Outcomes and Measures of Quality of Life
Joel Kremer¹, Kevin Kane², George Reed³ and Michael Weinblatt⁴, ¹The Corrona Research Foundation, Delray Beach, FL, ²U of Mass Medical School, Worcester, MA, MA, ³University of Massachusetts Chan Medical School, Worcester, MA, ⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: Low disease activity has been identified as a treatment goal for the treatment of RA. A singlecenter RA registry (BRASS) reported a difference in…
Abstract Number: 0432 • ACR Convergence 2025
Frequency and Characteristics of Ophthalmologic Involvement in Patients with Rheumatoid Arthritis
Javier Federico Flores Trejo¹, Joan Manuel Dapeña², Florencia Micaela Pascual³, Graciela Liliana Ghiglione¹, Juan Manuel Bande³, María Alejandra Medina³, José Angel Caracciolo³ and Silvia Beatriz Papasidero³, ¹Hospital General de Agudos Dr. Enrique Tornú, Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ²Sanatorio Dr Julio Méndez, CABA, Ciudad Autonoma de Buenos Aires, Argentina, ³Hospital General de Agudos Dr. Enrique Tornú, Buenos Aires, Argentina
Background/Purpose: Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease that primarily affects synovial joints but may also involve extra-articular organs. Ocular involvement is one…
Abstract Number: 0259 • ACR Convergence 2025
Inhaled pirfenidone as an innovative therapeutic approach to treat autoimmune ILD and other forms of Progressive Pulmonary Fibrosis: Phase 2b Study Design
Kristin Highland¹, Colin Reisner², Allison Trucillo³, Deepthi Nair⁴, Felix Woodhead⁴, Howard Lazarus⁴, Craig Conoscenti⁴ and Martin Kolb⁵, ¹Cleveland Clinic, Shaker Heights, OH, ²DevPro Biopharma, Basking Ridge, NJ, ³Avalyn Pharma, Austin, TX, ⁴Avalyn Pharma, Cambridge, MA, ⁵McMaster University, Hamilton, ON, Canada
Background/Purpose: Progressive Pulmonary Fibrosis (PPF) is an increasingly recognized condition, defined in 2022 to address the progression of pulmonary fibrosis in patients with interstitial lung…
Abstract Number: 0167 • ACR Convergence 2025
Geographic and Demographic Patterns of Rheumatoid Arthritis in the United States: Insights from GBD 2021
Punith Chirumamilla¹, Sameer Kumar Majety², Rithish Nimmagadda³, Ravi Medarametla⁴, Priya Sunkara⁵, Pranathi Bandarupalli⁶, Anjani Mahesh Kumar Cherukuri⁷ and Himaja Anne⁸, ¹Baptist Memorial Hospital North Mississippi, Oxford, MS, ²School of Medicine, Xiamen University, China, Kakinada, Andhra Pradesh, India, ³One Brooklyn Health, New York, NY, ⁴Mamata Medical College, Guntur, Andhra Pradesh, India, ⁵White River Health, Batesville, AZ, ⁶Mercy St Vincent Medical Center, Toledo, OH, ⁷Guntur Medical College, Guntur, Andhra Pradesh, India, ⁸Hind Institute of Medical Sciences, Sitapur, Uttar Pradesh, India
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune, systemic disease with a rising U.S. healthcare burden. Utilizing Global Burden of Disease (GBD) 2021 estimates, we analyzed…
Abstract Number: 0087 • ACR Convergence 2025
Integrative Metabolomic and Inflammatory Profiling in Rheumatoid Arthritis: Disease activity, therapeutic modulation, and underlying hepatic mechanisms
Laura muñoz-Barrera¹, Carlos Pérez Sánchez², Rafaela Ortega-Castro³, Sagrario Corrales¹, Tomás Cerdó¹, Ismael Sanchez-Pareja¹, Pilar Font⁴, Jerusalen Calvo Gutierrez⁵, M Carmen Abalos-Aguilera⁶, Desiree Ruiz-Vilchez⁷, Pedro Seguí-Azpilcueta⁸, Christian Merlo-Ruiz⁶, Jose Javier Pérez Venegas⁹, DOLORES RUIZ MONTESINOS¹⁰, Carmen Maria Romero Barco¹¹, Antonio Fernández-Nebro¹², Natalia Mena Vázquez¹³, FRANCISCO JAVIER GODOY NAVARRETE¹⁴, ALBA MARIA CABEZAS LUCENA¹⁵, MARIA ANGELES AGUIRRE ZAMORANO¹, Nuria Barbarroja¹⁶, Alejandro Escudero¹⁷ and Chary López pedrera¹⁸, ¹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ³Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ⁴Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, SpainBiomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ⁵Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Sevilla, Spain, ⁶Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ⁷Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, ⁸Radiology Service, Reina Sofia Hospital/Maimonides Institute for Research in Biomedicine of Cordoba/University of Cordoba, Spain, Córdoba, United Kingdom, ⁹Virgen Macarena University Hospital, Sevilla, Spain, Sevilla, Spain, ¹⁰Virgen Macarena University Hospital, Sevilla, Spain, Cordoba, ¹¹Virgen de la Victoria Hospital Malaga, Spain, Malaga, Spain, ¹²Hospital Regional Universitario de Malaga, Malaga, Spain, Malaga, Spain, ¹³Hospital Regional Universitario de Malaga, Malaga, Spain, Málaga, Spain, ¹⁴Jaen University Hospital, Spain, Jaen, Spain, ¹⁵Jaen University Hospital, Spain, Jaen, ¹⁶Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ¹⁷Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Andalucia, Spain, ¹⁸Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain
Background/Purpose: Lipid metabolism plays a key role in immune cell plasticity, influencing activation, differentiation and function. Inflammation alters this metabolism, contributing to disease progression. Extensive…
Abstract Number: 0069 • ACR Convergence 2025
Spatial transcriptomics in rheumatoid arthritis (RA) synovium reveals distinct region-specific fibroblast functions
Camilla R.L. Machado¹, Mina Yao¹, David Boyle², Robert J. Benschop³, James T. Parker³, Wei Wang² and Gary Firestein¹, ¹University of California, San Diego, San Diego, CA, ²University of California, San Diego, San Diego, ³Eli Lilly, San Diego
Background/Purpose: RA synovium displays cellular heterogeneity, with gene expression driving disease pathogenesis. Unbiased cell-specific transcriptomes in RA synovium have previously relied primarily on disaggregated tissues…
Abstract Number: 0033 • ACR Convergence 2025
Development and Internal Validation of Two Human Leukocyte Antigen Genetic Risk Scores for Predicting Rheumatoid Arthritis Progression and Anti-Citrullinated Protein Antibody-Positivity
Lauren Vanderlinden¹, Jun Inamo², Jennifer Seifert³, V. Michael Holers⁴, Joel Guthridge⁵, Kevin Deane⁶ and Fan Zhang⁷, ¹University of Colorado Anschutz Medical Campus, Monument, CO, ²University of Colorado School of Medicine, Aurora, CO, ³University of Colorado and Oklahoma Medical Research Foundation, Aurora, CO, ⁴University of Colorado, Denver, CO, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ⁷The University of Colorado, Aurora, CO
Background/Purpose: Human leukocyte antigen (HLA) class II genes play a central role in antigen presentation and immune modulation. The shared epitope (SE) region within HLA-DRB1…
Abstract Number: 2642 • ACR Convergence 2025
Impact of Rheumatoid Arthritis Therapeutic Classes on Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism: A Population-Based Cohort Study
Mohammad Movahedi¹, Angela Cesta¹, Sibel Aydin², Pooneh Akhavan³, Tetyana Kendzerska⁴, Claire Bombardier¹ and Bindee Kuriya⁵, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Department of Medicine, University of Ottawa, The Ottawa Hospital Research Institute, Ottawa, ON, Canada, ³self-employed, Toronto, ON, Canada, ⁴Ottawa Hospital Research Institute, Mississuaga, ON, Canada, ⁵University of Toronto - Toronto, Toronto, ON, Canada
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of major adverse cardiovascular events (MACE) and venous thromboembolism (VTE). Inflammation is a driver of…
Abstract Number: 2397 • ACR Convergence 2025
Analytical Performance of a Fully Automated Multiplexed Microarray Immunoassay for the Simultaneous Detection of Fifteen Autoantibodies Associated with Connective Tissue Diseases in a Reference Laboratory in Southern France
Guillaume Nardella¹, Gerber Gomez², Christian Fischer² and Claire Monat¹, ¹Inovie Labosud Provence, Specialized Autoimmunity Analyses, Marseille, France, ²Scientific & Medical Affairs, AliveDx Suisse SA, Eysins, Switzerland
Background/Purpose: Autoantibodies are key diagnostic markers in autoimmune connective tissue diseases (CTD). Conventional testing often requires multiple single-measurand assays, which can be labor-intensive and time-consuming.…
Abstract Number: 2274 • ACR Convergence 2025
Importance Of Fc Region On Therapeutic Survival In Rheumatoid Arthritis Patients With Anti-TNF Therapy
ELENA GRAU GARCIA¹, Iago Alcántara Álvarez², Jose Ivorra Cortes³, Pablo Muñoz Martinez⁴, Laura Mas Sanchez⁵, Alba Maria Torrat Noves⁶, Daniel Ramos Castro⁷, Belen Villanueva Manes⁸, Miguel Simeo Vinaixa⁴, Andres Perez Hurtado⁹ and José Andrés Román Ivorra¹⁰, ¹HUP La Fe, Valencia, Comunidad Valenciana, Spain, ²Hospital Universitari i Politénic La Fe, València, Spain, ³Hospital Universitario La Fe, Valencia, Comunidad Valenciana, Spain, ⁴Rheumatology Department. HUP La Fe, Valencia, Spain, ⁵Hospital Universitari i Politecnic La Fe, València, Spain, ⁶Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Spain, ⁷Hospital Universitari i Politecnic La Fe, Valencia, Spain, ⁸Hospital La Fe, València, Spain, ⁹Hospital Universitario y Politècnico La Fe, València, Comunidad Valenciana, Spain, ¹⁰Hospital Universitari i Politècnic La Fe, Valencia, Spain
Background/Purpose: In patients affected by rheumatoid arthritis (RA), it has been studied a relation between high rheumatoid factor (RF) and a favorable response to anti-TNF…
Abstract Number: 2259 • ACR Convergence 2025
Lung Transplant Outcomes in Patients with Rheumatoid Arthritis Associated Interstitial Lung Disease Compared to Idiopathic Pulmonary Fibrosis: A Multicentric Retrospective Analysis and Meta-analysis
Saud AlHajeri¹, Matthew Major², Darya S. Jalaledin³, Beatrice Daviault⁴, Arusa Shah⁵, Alec Yu⁶, Sabrina Hoa⁷, Robert Levy⁸, Jennifer Wilson¹, Charles Poirier⁴, James Choi⁶, John Yee⁶, Océane Landon-Cardinal⁹, Kun Huang¹⁰ and Hyein Kim¹¹, ¹UBC, Vancouver, BC, Canada, ²University of British Columbia, Vancouver, Canada, ³Université de Montréal, Saint-Lambert, QC, Canada, ⁴University of Montreal, Montreal, QC, Canada, ⁵University of Montreal, Montreal, BC, Canada, ⁶University of British Columbia, Vancouver, BC, Canada, ⁷University of Montreal, Brossard, QC, Canada, ⁸University of British Columbia, Deerfield, IL, ⁹Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, ¹⁰University of British Columbia, Vancouver, Surrey, BC, Canada, ¹¹The University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Interstitial lung disease (ILD) is a frequent complication of rheumatoid arthritis (RA), ranging from subclinical ILD to advanced fibrosis, and is associated with significant…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].